Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
308.69B
Market cap308.69B
Price-Earnings ratio
20.44
Price-Earnings ratio20.44
Dividend yield
2.21%
Dividend yield2.21%
Average volume
1.79M
Average volume1.79M
High today
$150.75
High today$150.75
Low today
$149.56
Low today$149.56
Open price
$150.21
Open price$150.21
Volume
2.08M
Volume2.08M
52 Week high
$170.46
52 Week high$170.46
52 Week low
$97.72
52 Week low$97.72

NVS News

TipRanks 21h
Novartis announces two-year results from Phase III APPLAUSE-IgAN study

Novartis (NVS) announced final two-year results from the Phase III APPLAUSE-IgAN study of Fabhalta in IgA nephropathy, IgAN. Fabhalta demonstrated a statistical...

Benzinga 3d
Novartis Bets $2 Billion To Deepen Allergy Drug Pipeline

Novartis Expands Allergy Portfolio IgE-driven (IgE-mediated) diseases are type I hypersensitivity reactions where immunoglobulin E antibodies trigger mast cell...

Novartis Bets $2 Billion To Deepen Allergy Drug Pipeline
TipRanks 3d
Novartis to buy biotech company Excellergy for up to $2B

Novartis (NVS) announced that it has entered into an agreement to acquire Excellergy, Inc., a private biotech company developing next-generation anti-IgE therap...

Analyst ratings

48%

of 27 ratings
Buy
37%
Hold
48.1%
Sell
14.8%

More NVS News

TipRanks 4d
Novartis Stock Rises on $2B Excellergy Acquisition to Expand Allergy Portfolio

Shares of Swiss drugmaker Novartis (NVS) are slightly up in pre-market hours today after the company announced the acquisition of U.S.-based biotech company Exc...

TipRanks 4d
Novartis price target raised to $170 from $143 at Morgan Stanley

Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Novartis (NVS) to $170 from $143 and keeps an Overweight rating on the shares. The f...

TipRanks 4d
Novartis: Late-Stage Pipeline and Pelacarsen Upside Support Buy Rating Despite Patent Headwinds

In a report released today, Sachin Jain from Bank of America Securities reiterated a Buy rating on Novartis AG, with a price target of CHF140.00. Sachin Jain h...

TipRanks 4d
Enliven price target raised to $56 from $48 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Enliven (ELVN) to $56 from $48 and keeps a Buy rating on the shares. The firm believes Merck’s (MRK) acquisiti...

24/7 Wall St. 6d
There Are Three Things Driving Amplify's 5.1%. Yield Higher | IDVO

There Are Three Things Driving Amplify’s 5.1%. Yield Higher | IDVO By John Seetoo Published Mar 24, 10:03AM EDT Quick Read Amplify CWP International Enhanced...

There Are Three Things Driving Amplify's 5.1%. Yield Higher | IDVO

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.